Journal ArticleDOI
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik,Steven Shak,Gong Tang,Chungyeul Kim,Joffre B. Baker,Maureen T. Cronin,Frederick L. Baehner,Michael G. Walker,Drew Watson,Taesung Park,William Hiller,Edwin R. Fisher,D. Lawrence Wickerham,John Bryant,Norman Wolmark +14 more
Reads0
Chats0
TLDR
The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.Abstract:
background The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor–positive tumors is poorly defined by clinical and histopathological measures. methods We tested whether the results of a reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancerrelated genes and 5 reference genes were used in a prospectively defined algorithm to calculate a recurrence score and to determine a risk group (low, intermediate, or high) for each patient. results Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks. The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent, respectively. The Kaplan–Meier estimates of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 percent (95 percent confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group (P<0.001). In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size (P<0.001). The recurrence score was also predictive of overall survival (P<0.001) and could be used as a continuous function to predict distant recurrence in individual patients. conclusions The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor–positive breast cancer.read more
Citations
More filters
Journal ArticleDOI
Biomarkers of peripheral arterial disease.
John P. Cooke,Andrew Wilson +1 more
TL;DR: The focus of this review is on proteomic biomarkers associated with PAD, which may provide novel insights into the pathophysiology of PAD and new therapeutic avenues to pursue.
Journal ArticleDOI
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.
Jeffrey B. Smerage,G. Thomas Budd,Gerald V. Doyle,Marty Brown,Constanza Paoletti,Maria C. Muñiz,M. Craig Miller,Madeline Repollet,David Allen Chianese,Mark Connelly,Leon W.M.M. Terstappen,Daniel F. Hayes +11 more
TL;DR: Analysis of apoptosis & Bcl‐2 expression in CTC from patients being treated for metastatic breast cancer is estimated to add additional prognostic and predictive information.
Journal ArticleDOI
Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures
Thomas Karn,Lajos Pusztai,Uwe Holtrich,Takayuki Iwamoto,Christine Y. Shiang,Marcus Schmidt,Volkmar Müller,Christine Solbach,Regine Gaetje,Lars Hanker,A. Ahr,Cornelia Liedtke,Eugen Ruckhäberle,Manfred Kaufmann,Achim Rody +14 more
TL;DR: A 264-gene prognostic signature for TNBC was identified which is unrelated to previously known prognostic signatures and had modest predictive value, however, the combination of a B-cell metagene with the prognostic signs increased its response predictive value.
Journal ArticleDOI
Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer
Fares Al-Ejeh,Peter T. Simpson,J M Sanus,Kerenaftali Klein,Murugan Kalimutho,Wei Shi,Mariska Miranda,Mariska Miranda,Jamie R. Kutasovic,Ashwini Raghavendra,Jason Madore,Lynne Reid,Lutz Krause,Georgia Chenevix-Trench,Sunil R. Lakhani,Sunil R. Lakhani,Kum Kum Khanna,Kum Kum Khanna +17 more
TL;DR: Meta-analysis of TNBC gene expression profiles provides evidence that mitosis-independent expression of TTK protein was prognostic in TNBC and other aggressive breast cancer subgroups, suggesting that protection of CIN/aneuploidy drives aggressiveness and treatment resistance.
Journal ArticleDOI
The influence of a gene expression profile on breast cancer decisions.
Leonard R. Henry,Alexander Stojadinovic,Alexander Stojadinovic,Sandra M. Swain,Sheila A. Prindiville,Rose Cordes,Peter W. Soballe +6 more
TL;DR: The Oncotype Dx® Recurrence Score (RS), is often employed in patients with estrogen receptor‐positive, node negative (ER+LN−) breast cancer and the effect of the assay on a panel of breast oncology experts is investigated.
References
More filters
Journal ArticleDOI
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
Todd R. Golub,Todd R. Golub,Donna K. Slonim,Pablo Tamayo,Christine Huard,Michelle Gaasenbeek,Jill P. Mesirov,Hilary A. Coller,Mignon L. Loh,James R. Downing,Michael A. Caligiuri,Clara D. Bloomfield,Eric S. Lander +12 more
TL;DR: A generic approach to cancer classification based on gene expression monitoring by DNA microarrays is described and applied to human acute leukemias as a test case and suggests a general strategy for discovering and predicting cancer classes for other types of cancer, independent of previous biological knowledge.
Journal ArticleDOI
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Therese Sørlie,Charles M. Perou,Robert Tibshirani,Turid Aas,Stephanie Geisler,Hilde Johnsen,Trevor Hastie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,T. Thorsen,Hanne Quist,John C. Matese,Patrick O. Brown,David Botstein,Per Eystein Lønning,Anne Lise Børresen-Dale +16 more
TL;DR: Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
Journal ArticleDOI
Quantitative monitoring of gene expression patterns with a complementary DNA microarray.
TL;DR: A high-capacity system was developed to monitor the expression of many genes in parallel by means of simultaneous, two-color fluorescence hybridization, which enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA.
Journal ArticleDOI
Gene expression profiling predicts clinical outcome of breast cancer
Laura J. van't Veer,Hongyue Dai,Marc J. van de Vijver,Yudong D. He,Augustinus A. M. Hart,Mao Mao,Hans Peterse,Karin van der Kooy,Matthew J. Marton,Anke T. Witteveen,George J. Schreiber,Ron M. Kerkhoven,Christopher J. Roberts,Peter S. Linsley,René Bernards,Stephen H. Friend +15 more
TL;DR: DNA microarray analysis on primary breast tumours of 117 young patients is used and supervised classification is applied to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis, providing a strategy to select patients who would benefit from adjuvant therapy.
Related Papers (5)
Gene expression profiling predicts clinical outcome of breast cancer
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
Marc J. van de Vijver,Yudong D. He,Laura J. van't Veer,Hongyue Dai,Augustinus A. M. Hart,D.W. Voskuil,George J. Schreiber,Johannes L. Peterse,Christopher J. Roberts,Matthew J. Marton,Mark Parrish,Douwe Atsma,Anke T. Witteveen,Annuska M. Glas,Leonie J. M. J. Delahaye,Tony van de Velde,Harry Bartelink,Sjoerd Rodenhuis,Emiel J. Th. Rutgers,Stephen H. Friend,René Bernards +20 more
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more